Of more than 2,600 US healthcare workers who participated in a nationwide online panel survey from 2022 to 2023, 26% reported ...

By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

Is it anxiety or a panic attack? Discover the key differences and learn why understanding them matters for managing your ...

Intra-Cellular recently guided to at least $5 billion in peak Caplyta sales. Intra-Cellular’s stock was trading at $127.48, up $32.61, or 34%. J&J’s stock (NYSE:JNJ) was selling for $143.39, up $1.34.

It’s hard to know how long anxiety disorders will last when you’re in the thick of them. It was during the mid-2000s that my ...

Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression ... stage pipeline with best-in-disease potential in generalized anxiety ...

Jan. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug ...

This breakthrough suggests a potential treatment approach for the entire spectrum of lissencephaly disorders. Yale researchers identified an underactive mTOR pathway as a cause of lissencephaly and ...

Further, this research, published in Nature, offers a path for potential treatments. “Lissencephaly belongs to a group of disorders we call malformations of cortical development,” said ...

Treatment can involve targeted medications or careful monitoring. Myeloproliferative disorders are a group of cancers involving the uncontrolled replication of cells derived from myeloid stem cells.

The disorders are often associated with seizures and intellectual disability and currently there are no available treatments. A new study, however, has identified a molecular mechanism that ...